GoodRx Holdings, Inc. (GDRX)
NASDAQ: GDRX · Real-Time Price · USD
3.060
+0.030 (0.99%)
At close: Nov 12, 2025, 4:00 PM EST
3.070
+0.010 (0.34%)
After-hours: Nov 12, 2025, 7:59 PM EST
GoodRx Holdings Revenue
GoodRx Holdings had revenue of $196.03M in the quarter ending September 30, 2025, with 0.40% growth. This brings the company's revenue in the last twelve months to $800.65M, up 1.30% year-over-year. In the year 2024, GoodRx Holdings had annual revenue of $792.32M with 5.61% growth.
Revenue (ttm)
$800.65M
Revenue Growth
+1.30%
P/S Ratio
1.40
Revenue / Employee
$1,084,893
Employees
738
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 792.32M | 42.06M | 5.61% |
| Dec 31, 2023 | 750.27M | -16.29M | -2.12% |
| Dec 31, 2022 | 766.55M | 21.13M | 2.83% |
| Dec 31, 2021 | 745.42M | 194.72M | 35.36% |
| Dec 31, 2020 | 550.70M | 162.48M | 41.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GDRX News
- 7 days ago - GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - GoodRx Sees ‘Profund Transformation' in Prescriptions With TrumpRx - PYMNTS
- 8 days ago - GoodRx Reports Third Quarter 2025 Results - Business Wire
- 8 days ago - Should You Buy GoodRx Stock? - Forbes
- 4 weeks ago - GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment - Business Wire
- 4 weeks ago - GoodRx: Novo Deal And TrumpRx Talks Point To Ebitda/FCF Upside - Seeking Alpha
- 4 weeks ago - Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch - Benzinga
- 4 weeks ago - Exclusive: US pharmacies, drug discounters are discussing TrumpRx role with administration - Reuters